Type segmentation classifies serological assays into ELISA, lateral flow immunoassay (LFIA), chemiluminescence immunoassay (CLIA), and emerging rapid diagnostic platforms. ELISA, accounting for approximately 40 % of market volume, remains the workhorse for laboratory‑based quantitative analysis due to its scalability and validated performance across infectious‑disease panels. LFIA, contributing near 35 % of revenue, offers point‑of‑care convenience, enabling decentralized testing in outpatient clinics and field settings, albeit with lower analytical sensitivity. CLIA captures roughly 20 % of the market, distinguished by high‑throughput automation and superior signal‑to‑noise ratios, which command premium pricing in hospital networks. The remaining 5 % comprises novel rapid diagnostic platforms such as microfluidic immunoassays and digital immuno‑chromatography, which are gaining traction through integration with mobile health ecosystems. This Serological Testing market taxonomy illustrates how each type’s technological attributes, cost structure, and deployment context shape its share of total market size, guiding investment and product‑development priorities. Regulatory clearance pathways differ among these formats; ELISA and CLIA benefit from established FDA 510(k) routes, while LFIA and emerging platforms often rely on Emergency Use Authorizations, influencing time‑to‑market and pricing dynamics.
